Table 5.

TRAEs in the study population.

	All grades of TRAE			TRAE (more than grade 3)
	HAIC+L+P (n = 75)	HAIC+L (n = 74)	p-value	HAIC+L+P (n = 75)	HAIC+L (n = 74)	p-value
Fever (n (%))	8 (10.66%)	9 (12.16%)	0.774
Decreased appetite (n (%))	24 (32.00%)	18 (24.32%)	0.298
Abdominal pain (%)	40 (53.33%)	35 (47.29%)	0.461
Nausea/vomiting (no (%))	4 (5.33%)	6 (8.10%)	0.499
Elevated serum AST or ALT (n (%))	25 (33.33%)	26 (35.13%)	0.817
Thrombocytopenia (n (%))	16 (21.33%)	10 (13.51%)	0.209
Gastrointestinal hemorrhage (n (%))	10 (13.33%)	11 (14.86%)	0.788
Hyperbilirubinemia (n (%))	19 (25.33%)	22 (30.13%)	0.548	4 (5.33%)	2 (2.70%)	0.689
Albumin decreased (n (%))	13 (17.33%)	11 (14.86%)	0.682
Neutropenia (n (%))	8 (10.66%)	11 (14.86%)	0.442
Creatinine increased (n (%))	30 (40.00%)	27 (36.48%)	0.659
Liver abscess (n (%))	1 (1.33%)	2 (2.70%)	0.548
Cholesteatoma (n (%))	2 (2.66%)	3 (4.05%)	0.638
Cholecystitis (n (%))	1 (1.33%)	2 (0.00%)	0.548
Hypertension (n (%))	21 (28.00%)	10 (13.51%)	0.029	3 (4.00%)	1 (1.35%)	0.622
Hand–foot skin reaction (n (%))	29 (38.66%)	22 (29.72%)	0.250
Skin rash (n (%))	16 (21.33%)	14 (18.91%)	0.713	2 (2.66%)	3 (4.05%)	0.638
Proteinuria (n (%))	21 (28.00%)	15 (20.27%)	0.250
Fatigue (n (%))	27 (36.00%)	28 (37.83%)	0.816	1 (1.33%)	2 (4.00%)	0.548
Bleeding (gingiva; n (%))	4 (5.33%)	5 (6.75%)	0.745
Diarrhea (n (%))	11 (14.66%)	18 (24.32%)	0.137

HAIC, hepatic artery infusion chemotherapy; AST, aspartate aminotransferase; ALT, alanine aminotransferase.